
CORRIGENDUM

Integrins in cancer: biological implications and therapeutic opportunities

Jay S. Desgrosellier & David A. Cheresh

Nature Reviews Cancer 10, 9–22 (2010)

On page 17 of this article, in the section *Targeting $\alpha v \beta 3$ and $\alpha v \beta 5$* the sentence at the start of the second paragraph that reads “Cilengitide is an inhibitor of both $\alpha v \beta 3$ and $\alpha v \beta 5$ integrins, and it was selected in our laboratory by screening a library of cyclic RGD peptides in a cell-free receptor assay for their capacity to inhibit integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ but not $\alpha IIb \beta 3$ (REF. 130).” was incorrectly phrased. The corrected sentence with additional references is given below.

“Cilengitide is an inhibitor of both $\alpha v \beta 3$ and $\alpha v \beta 5$ integrins. We had shown that $\alpha v \beta 3$ and $\alpha v \beta 5$ integrins were important regulators of angiogenesis and tumour growth^{191,192} and developed a cell-free receptor assay to select for antagonists of integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ that did not effect integrin $\alpha IIb \beta 3$ (REF. 130). This assay was used to screen a library of integrin binding cyclic RGD peptides designed and synthesized by H. Kessler and colleagues for $\alpha v \beta 3$ activity and selectivity^{193–195} from which cilengitide was developed¹⁹⁶.”

191. Cheresh, D. A. Human endothelial cells synthesize and express an Arg Gly Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. *Proc. Natl. Acad. Sci. USA* **84**, 6471–6475 (1987).
192. Brooks, P. C. *et al.* Integrin $\alpha v \beta 3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. *Cell* **79**, 1157–1164 (1994).
193. Aumailley, M. *et al.* Arg Gly Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. *FEBS Lett.* **291**, 50–54 (1991).
194. Gurrath, M. *et al.*, Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides; *Eur. J. Biochem.*, **210**, 911–921 (1992).
195. Pfaff, M. *et al.*, Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by $\alpha IIb \beta 3$, $\alpha V \beta 3$ and $\alpha 5 \beta 1$ Integrins. *J. Biol. Chem.*, **269**, 20233–20238 (1994).
196. Dechantsreiter, M. A. *et al.* N-Methylated cyclic RGD peptides as highly active and selective $\alpha_v \beta_3$ integrin antagonists. *J. Med. Chem.* **42**, 3033–3040 (1999).